You are invited to join AFMC for a complimentary educational webinar:
Monoclonal Antibodies – Response to the COVID-19 Outbreak
Friday, Feb. 5
12:30 – 1:30 p.m.
Audience: Primary Care Providers, Specialists and Nurses
Please join AFMC’s Chief Medical Officer, Dr. Chad Rodgers and Dr. Atul Kothari, Senior Physician Specialist with the Arkansas Department of Health as they discuss and share information on Monoclonal Antibodies – Response to the COVID-19 Outbreak.
Monoclonal antibodies are laboratory-made proteins that mimic your immune system’s ability to fight off COVID-19. The FDA issued an Emergency Use Authorization (EUA) to allow the use of monoclonal antibodies for the treatment of mild to moderate symptoms of COVID-19 in adults and pediatric patients.
• Who is eligible for the monoclonal antibody therapy?
• Benefits of antibody therapy
• Where can patients receive treatment?
In response to the COVID-19 outbreak in Arkansas, the Division of Medical Services (DMS) is now covering administration of monoclonal antibodies.